Scassellati Sforzolini discusses the significance of Galderma’s nemolizumab receiving 4 additional filing acceptances for prurigo nodularis and atopic dermatitis.
Baldo Scassellati Sforzolini, MD, PhD, MBA
Advertisement
Articles by Baldo Scassellati Sforzolini, MD, PhD, MBA
Advertisement
Latest Updated Articles
Baldo Scassellati Sforzolini, MD, PhD, MBA: Expanding Nemolizumab’s AccessPublished: May 17th 2024 | Updated:
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Derm Dispatch: What 'Free to Be Me' Means to Tori Spelling and Stella McDermott
3
Reviewing Type 2 Inflammation Through a Different Lens
4
Alpha-9 Begins First-in-Human Trial of MC1R-Targeted Radiotherapeutic
5
